Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
Biogen paid Ionis a US $ 60 million one-time upfront payment
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness
The newly launched centre in Mumbai is part of the company’s ambition to be present in 100 cities across the country within two years.”
Subscribe To Our Newsletter & Stay Updated
